Aclys Bio discovers and develops precision biologics for the treatment of cancer. Aclys has identified a set of novel precision and immune-oncology targets from the tumor molecular profiles of tens of thousands of cancer patients and is building antibody-based therapies against each target, both for internal development, and for partnership. Aclys’s Precision ImmunoLogical Antibody™ discovery platform (PILA™ or PILA Platform™) enables Aclys’s rapid antibody engineering and optimization and evaluation. The resultant new class of highly developable precision biologics has unique potential to decrease clinical trial times, costs, and risk, while improving trial success rates and ultimately, patient lives.
Target Selection
Aclys employs a combination of computational methods and rational design, informed by the tumor profiles of >30,000 cancer patients.
Antibody Discovery/Optimization
Aclys’s proprietary mammalian cell-based discovery and optimization platform yields antibodies of the highest quality on an accelerated timeline.
Preclinical Proof-of-Concept
Fully integrated high speed antibody expression and proof-of-concept assays, including our in vitro and in vivo evaluation.
Partnering
Aclys collaborates with the world’s leading drug developers to maximize the impact of our pipeline.
